Acumen Pharmaceuticals Statistics
Total Valuation
ABOS has a market cap or net worth of $224.18 million. The enterprise value is $145.63 million.
| Market Cap | 224.18M |
| Enterprise Value | 145.63M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABOS has 72.32 million shares outstanding. The number of shares has increased by 6.39% in one year.
| Current Share Class | 72.32M |
| Shares Outstanding | 72.32M |
| Shares Change (YoY) | +6.39% |
| Shares Change (QoQ) | +14.29% |
| Owned by Insiders (%) | 14.60% |
| Owned by Institutions (%) | 34.77% |
| Float | 37.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.91 |
| P/TBV Ratio | 3.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.47, with a Debt / Equity ratio of 0.55.
| Current Ratio | 2.47 |
| Quick Ratio | 2.38 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.41 |
Financial Efficiency
Return on equity (ROE) is -120.50% and return on invested capital (ROIC) is -55.81%.
| Return on Equity (ROE) | -120.50% |
| Return on Assets (ROA) | -45.77% |
| Return on Invested Capital (ROIC) | -55.81% |
| Return on Capital Employed (ROCE) | -152.43% |
| Weighted Average Cost of Capital (WACC) | 6.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +102.61% in the last 52 weeks. The beta is 0.33, so ABOS's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +102.61% |
| 50-Day Moving Average | 2.47 |
| 200-Day Moving Average | 2.40 |
| Relative Strength Index (RSI) | 72.69 |
| Average Volume (20 Days) | 371,975 |
Short Selling Information
The latest short interest is 3.37 million, so 4.66% of the outstanding shares have been sold short.
| Short Interest | 3.37M |
| Short Previous Month | 2.81M |
| Short % of Shares Out | 4.66% |
| Short % of Float | 9.09% |
| Short Ratio (days to cover) | 8.83 |
Income Statement
| Revenue | n/a |
| Gross Profit | -86.79M |
| Operating Income | -105.42M |
| Pretax Income | -105.04M |
| Net Income | -105.04M |
| EBITDA | -105.37M |
| EBIT | -105.42M |
| Earnings Per Share (EPS) | -$1.64 |
Balance Sheet
The company has $110.20 million in cash and $31.65 million in debt, with a net cash position of $78.55 million or $1.09 per share.
| Cash & Cash Equivalents | 110.20M |
| Total Debt | 31.65M |
| Net Cash | 78.55M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 57.26M |
| Book Value Per Share | 0.79 |
| Working Capital | 68.67M |
Cash Flow
| Operating Cash Flow | -91.79M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 50,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -91.79M |
| FCF Per Share | -$1.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.39% |
| Shareholder Yield | -6.39% |
| Earnings Yield | -46.86% |
| FCF Yield | -40.94% |
Analyst Forecast
The average price target for ABOS is $7.40, which is 138.71% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.40 |
| Price Target Difference | 138.71% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |